Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMOHUA)

Drug Name
Contezolid acefosamil Drug Info
Synonyms
JANNTEAGZXJITO-BTQNPOSSSA-M; UNII-T79C086548; T79C086548; Contezolid acefosamil [USAN]; CHEMBL3989966; Acetic acid, anhydride with N-(((5R)-3-(4-(3,4-dihydro-4-oxo-1(2H)-pyridinyl)-2,3,5-trifluorophenyl)-2-oxo-5-oxazolidinyl)methyl)-N-3-isoxazolylphosphoramidic acid, sodium salt (1:1:1); Acetic (5R)-isoxazol-3yl((2-oxo-3-(2,3,5-trifluoro-4-(4-oxo-3,4-dihydropyridin-1(2H)-yl)phenyl)oxazolidin-5-yl)methyl)phosphoramidic anhydride, sodium salt (1:1); 1807365-35-0
Indication
Disease Entry ICD 11 Status REF
Acute bacterial skin infection 1C41 Phase 2 [1]
Cross-matching ID
PubChem CID
131750213
CAS Number
CAS 1807365-35-0
TTD Drug ID
DMMOHUA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Protein synthesis (hPRO synth)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Contezolid DMZ0F65 MRSA infection 1D01.0Y Phase 2 [1]
ARV-1801 DMUMFDU Melioidosis 1C42 Phase 2 [2]
Zilascorb (2H) DM3IRES Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Protein synthesis (hPRO synth) TTLIZBJ NOUNIPROTAC Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
3 Zilascorb(2H), a new reversible protein synthesis inhibitor: clinical study of an oral preparation. Anticancer Drugs. 1997 Mar;8(3):296-303.